Kaiming Li

Kaiming Li

Auto-generated profile, based on publicly available information

Kaiming Li

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MHMeixi Hao
Meixi Hao
SHSiyuan Hou
Siyuan Hou
WLWeishuo Li
Weishuo Li
KLKaiming Li
Kaiming Li
LXLingjing Xue
Lingjing Xue
CZCan Zhang
Can Zhang
Treatment of solid tumors with T cell therapy has yielded limited therapeutic benefits to date. Although T cell therapy in combination with proinflammatory cytokines or immune checkpoints inhibitors has demonstrated preclinical and clinical successes in a subset of solid tumors, unsatisfactory results and severe toxicities necessitate the development of effective and safe combinatorial strategies. Here, the liposomal avasimibe (a metabolism-modulating drug) was clicked onto the T cell surface by lipid insertion without disturbing the physiological functions of the T cell. Avasimibe could be restrained on the T cell surface during circulation and extravasation and locally released to increase the concentration of cholesterol in the T cell membrane, which induced rapid T cell receptor clustering and sustained T cell activation. Treatment with surface anchor-engineered T cells, including mouse T cell receptor transgenic CD8+ T cells or human chimeric antigen receptor T cells, resulted in superior antitumor efficacy in mouse models of melanoma and glioblastoma. Glioblastoma was completely eradicated in three of the five mice receiving surface anchor-engineered chimeric antigen receptor T cells, whereas mice in other treatment groups survived no more than 64 days. Moreover, the administration of engineered T cells showed no obvious systemic side effects. These cell-surface anchor-engineered T cells hold translational potential because of their simple generation and their safety profile.

10 September 2026 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
KLKaiming Li
Kaiming Li
XZXiaole Zhu
Xiaole Zhu
HWHaisi Wu
Haisi Wu
JLJiang Li
Jiang Li
FWFan Wu
Fan Wu
RXRui Xie
Rui Xie